On Monday, Shares of Petróleo Brasileiro S.A. - Petrobras (NYSE:PBR), gained 1.55% to $8.51, despite oil prices wavered between gains and losses Monday, then settled lower, on uncertainty about the pace of Iranian nuclear talks.
Light, sweet crude for August delivery closed down 54 cents, or 1%, at $52.20 a barrel on the New York Mercantile Exchange. Brent, the global benchmark, slipped 88 cents, or 1.5%, to $57.85 a barrel on ICE Futures Europe, WSJ Reports.
Today, oil prices declined more than $1 after Iran and six global powers reached a landmark nuclear deal that would see an easing of sanctions against Tehran and a gradual enhance in its oil exports.
Iran and the six powers have reached a deal that will grant Tehran sanctions relief in exchange for curbs on its nuclear programme, Iranian and Western diplomats said.
Petróleo Brasileiro S.A. Petrobras operates as an integrated energy company in Brazil and internationally. Its Exploration and Production segment engages in the exploration, development, and production of crude oil, natural gas liquids, and natural gas; and sale of crude oil and oil products produced at natural gas processing plants in domestic and foreign markets.
Shares of Eli Lilly and Company (NYSE:LLY), inclined 0.60% to $88.82, during its last trading session, hitting its highest level.
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) met recently to talk about the data supporting Eli Lilly and Company’s (LLY) necitumumab in combination with gemcitabine and cisplatin for use in first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC).
Squamous NSCLC is a devastating and difficult-to-treat form of lung cancer. The five-year survival rate for patients with metastatic disease is less than five percent.[1] Necitumumab in combination with gemcitabine and cisplatin is the first regimen to show a noteworthy improvement in overall survival over chemotherapy alone, specifically in the first-line setting.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
Finally, Fiserv, Inc. (NASDAQ:FISV), ended its last trade with 0.86% gain, and closed at $87.09, hitting its highest level.
Fiserv, declared the latest in a series of award wins for its clients in the Asia Pacific region with two wins at the Asia Customer Experience in Financial Services (CXFS) Awards. For initiatives executed in conjunction with Fiserv, Bangkok Bank was awarded Best Technology Implementation - Front-End, and Westpac Banking Corporation was awarded Best Omni-Channel Customer Experience. The CXFS Awards recognize industry leaders that are setting new standards in customer experience and engagement for the retail financial services sector.
The CXFS Award wins are the latest in a series of accolades for the banks. Westpac received the IT Innovation of the Year Award at the 2015 Retail Banker International Awards in addition to a Model Bank Award in the Omni-Channel category at Celent’s 2015 Innovation & Insight Day. Bangkok Bank won the Best Mobile Banking Project Award at the 2015 Asian Banker Technology Implementation Awards. These awards programs recognize excellence in retail banking and technology achievement in banking operations both globally and in Asia Pacific.
Fiserv, Inc., together with its auxiliaries, provides financial services technology worldwide. The company’s Payments and Industry Products segment provides debit, credit, and prepaid card processing and services; electronic bill payment and presentment services; Internet and mobile banking software and services; person-to-person payment services; and other electronic payments software and services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
